← Back to Clinical Trials
Recruiting NCT05556369

NCT05556369 Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05556369
Status Recruiting
Phase
Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Condition Cardiomyopathies
Study Type OBSERVATIONAL
Enrollment 288 participants
Start Date 2021-09-01
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 288 participants in total. It began in 2021-09-01 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cardiomyopathy refers to a diverse group of myocardial diseases with multiple causes. In 1995, the World Health Organization classified cardiomyopathies into hypertrophic, dilated, restrictive, and mixed type. This classification is based on the pathophysiology of the disease. However, with rapid evolution of molecular genetics in cardiology, the American Heart Association in 2006 has classified cardiomyopathies into two major groups based on predominant organ involvement and etiology; Primary cardiomyopathies are those solely or predominantly confined to heart muscle and are relatively few in number. Secondary cardiomyopathies show pathologic myocardial involvement as part of a large number and variety of generalized systemic (multiorgan) disorders.Current evidence supports the use of genetic testing in clinical practice to improve risk stratification for clinically affected patients and their at-risk relatives for cardiomyopathies.

Eligibility Criteria

Inclusion Criteria: * Presence of structural cardiomyopathy * First degree relatives for cardiomyopathy Exclusion Criteria: * Age \> 80 * Presence of sufficient conditions to explain the clinical condition of cardiomyopathy * Peripartum cardiomyopathy

Contact & Investigator

Central Contact

Stefano Carugo, Principal Investigator

✉ stefano.carugo@policlinico.mi.it

📞 +39 0255033579

Frequently Asked Questions

Who can join the NCT05556369 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cardiomyopathies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05556369 currently recruiting?

Yes, NCT05556369 is actively recruiting participants. Contact the research team at stefano.carugo@policlinico.mi.it for enrollment information.

Where is the NCT05556369 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT05556369 clinical trial?

NCT05556369 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 288 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology